SIG
44
-2
FSLR
47
3
CA
4
-10
MPC
62
32
EQT
31
-5
MCK
52
-3
HPE
51
-2
MMM
38
-6
YUM
39
-3
IP
54
3
NWL
50
-3
CNP
60
-5
NUE
50
-8
XRX
44
5
PNW
70
4
LMT
35
-14
HOG
33
-3
FIS
51
-4
HES
57
-2
CVS
37
-2
SIG
44
-2
FSLR
47
3
CA
4
-10
MPC
62
32
EQT
31
-5
MCK
52
-3
HPE
51
-2
MMM
38
-6
YUM
39
-3
IP
54
3
NWL
50
-3
CNP
60
-5
NUE
50
-8
XRX
44
5
PNW
70
4
LMT
35
-14
HOG
33
-3
FIS
51
-4
HES
57
-2
CVS
37
-2
Financhill
Back

UroGen Pharma 10K Form

Buy
51

URGN
UroGen Pharma

Last Price:
12.47
Seasonality Move:
5.53%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2023-11-14 10Q URGN/UroGen Pharma Quarterly
2023-08-10 10Q URGN/UroGen Pharma Quarterly
2023-05-11 10Q URGN/UroGen Pharma Quarterly
2022-11-10 10Q URGN/UroGen Pharma Quarterly
2022-08-11 10Q URGN/UroGen Pharma Quarterly
2022-05-10 10Q URGN/UroGen Pharma Quarterly

Receive URGN News And Ratings

See the #1 stock for the next 7 days that we like better than URGN

URGN Financial Statistics

Sales & Book Value

Annual Sales: $82.71M
Cash Flow: $-23.83M
Price / Cash Flow: 0
Annual Sales: $0.74
Price / Book: 17.32

Profitability

EPS (TTM): -3.22000
Net Income (TTM): $-113.58M
Gross Margin: $73.35M
Return on Equity: 0%
Return on Assets: -59.8%

UroGen Pharma Earnings Forecast

Key UroGen Pharma Financial Ratios

  • The Gross Profit Margin over the past 9 years for URGN is 88.68%.
  • The Selling, General & Administrative Expenses for URGN have been equal to 112.77% of Gross Profit Margin.
  • The Research & Development expenses have been 55.15% of Revenue.
  • The Interest Expense is -14.39% of Operating Income.
  • The Net Earning history of URGN is -123.61% of Total Revenues.
  • Per Share Earnings over the last 9 years have been positive in 4 years.

UroGen Pharma Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: URGN
CUSIP: M96088
Website: urogen.com

Debt

Debt-to-Equity Ratio: 3.23
Current Ratio: 8.15
Quick Ratio: 7.55

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

URGN Technical Analysis vs Fundamental Analysis

Buy
51
UroGen Pharma (URGN) is a Buy

Is UroGen Pharma a Buy or a Sell?

  • UroGen Pharma stock is rated a Buy
    The current UroGen Pharma [URGN] share price is $12.47. The Score for URGN is 51, which is 2% above its historic median score of 50, and infers lower risk than normal.